Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales

Current UK vaccination policy is to offer future COVID-19 booster doses to individuals at high risk of serious illness from COVID-19, but it is still uncertain which groups of the population could benefit most. In response to an urgent request from the UK Joint Committee on Vaccination and Immunisat...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The Lancet (British edition) Ročník 400; číslo 10360; s. 1305 - 1320
Hlavní autoři:	Agrawal, Utkarsh, Bedston, Stuart, McCowan, Colin, Oke, Jason, Patterson, Lynsey, Robertson, Chris, Akbari, Ashley, Azcoaga-Lorenzo, Amaya, Bradley, Declan T, Fagbamigbe, Adeniyi Francis, Grange, Zoe, Hall, Elliott C R, Joy, Mark, Katikireddi, Srinivasa Vittal, Kerr, Steven, Ritchie, Lewis, Murphy, Siobhán, Owen, Rhiannon K, Rudan, Igor, Shah, Syed Ahmar, Simpson, Colin R, Torabi, Fatemeh, Tsang, Ruby S M, de Lusignan, Simon, Lyons, Ronan A, O'Reilly, Dermot, Sheikh, Aziz
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Elsevier Ltd 15.10.2022 Elsevier Limited The Author(s). Published by Elsevier Ltd
Témata:	Aged BNT162 Vaccine ChAdOx1 nCoV-19 Cohort analysis Comorbidity Coronaviruses COVID-19 COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 Vaccines Datasets Death England - epidemiology Ethics Female Health care Hospitalization Humans Immunization Immunization, Secondary Immunosuppressive Agents Infections Kidney diseases Male Males Medical innovations Medical research Mortality mRNA Nations Northern Ireland Older people Pandemics Population Primary care Prospective Studies Regression analysis Regression models Risk analysis Risk factors Risk management SARS-CoV-2 Schedules Scotland Severe acute respiratory syndrome coronavirus 2 Vaccination Vaccines Viral diseases Wales - epidemiology England Scotland Northern Ireland Wales Israel United Kingdom > UK
ISSN:	0140-6736, 1474-547X, 1474-547X
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Current UK vaccination policy is to offer future COVID-19 booster doses to individuals at high risk of serious illness from COVID-19, but it is still uncertain which groups of the population could benefit most. In response to an urgent request from the UK Joint Committee on Vaccination and Immunisation, we aimed to identify risk factors for severe COVID-19 outcomes (ie, COVID-19-related hospitalisation or death) in individuals who had completed their primary COVID-19 vaccination schedule and had received the first booster vaccine. We constructed prospective cohorts across all four UK nations through linkages of primary care, RT-PCR testing, vaccination, hospitalisation, and mortality data on 30 million people. We included individuals who received primary vaccine doses of BNT162b2 (tozinameran; Pfizer–BioNTech) or ChAdOx1 nCoV-19 (Oxford–AstraZeneca) vaccines in our initial analyses. We then restricted analyses to those given a BNT162b2 or mRNA-1273 (elasomeran; Moderna) booster and had a severe COVID-19 outcome between Dec 20, 2021, and Feb 28, 2022 (when the omicron (B.1.1.529) variant was dominant). We fitted time-dependent Poisson regression models and calculated adjusted rate ratios (aRRs) and 95% CIs for the associations between risk factors and COVID-19-related hospitalisation or death. We adjusted for a range of potential covariates, including age, sex, comorbidities, and previous SARS-CoV-2 infection. Stratified analyses were conducted by vaccine type. We then did pooled analyses across UK nations using fixed-effect meta-analyses. Between Dec 8, 2020, and Feb 28, 2022, 17 337 580 individuals completed their primary vaccine schedule and 14 698 030 individuals received a booster dose. Between Dec 20, 2021, and Feb 28, 2022, 59 510 (0·3%) of the primary vaccine group and 26 100 (0·2%) of those who received their booster had severe COVID-19 outcomes. The risk of severe COVID-19 outcomes reduced after receiving the booster (rate change: 8·8 events per 1000 person-years to 7·6 events per 1000 person-years). Older adults (≥80 years vs 18–49 years; aRR 3·60 [95% CI 3·45–3·75]), those with comorbidities (≥5 comorbidities vs none; 9·51 [9·07–9·97]), being male (male vs female; 1·23 [1·20–1·26]), and those with certain underlying health conditions—in particular, individuals receiving immunosuppressants (yes vs no; 5·80 [5·53–6·09])—and those with chronic kidney disease (stage 5 vs no; 3·71 [2·90–4·74]) remained at high risk despite the initial booster. Individuals with a history of COVID-19 infection were at reduced risk (infected ≥9 months before booster dose vs no previous infection; aRR 0·41 [95% CI 0·29–0·58]). Older people, those with multimorbidity, and those with specific underlying health conditions remain at increased risk of COVID-19 hospitalisation and death after the initial vaccine booster and should, therefore, be prioritised for additional boosters, including novel optimised versions, and the increasing array of COVID-19 therapeutics. National Core Studies–Immunity, UK Research and Innovation (Medical Research Council), Health Data Research UK, the Scottish Government, and the University of Edinburgh.
AbstractList	Current UK vaccination policy is to offer future COVID-19 booster doses to individuals at high risk of serious illness from COVID-19, but it is still uncertain which groups of the population could benefit most. In response to an urgent request from the UK Joint Committee on Vaccination and Immunisation, we aimed to identify risk factors for severe COVID-19 outcomes (ie, COVID-19-related hospitalisation or death) in individuals who had completed their primary COVID-19 vaccination schedule and had received the first booster vaccine.BACKGROUNDCurrent UK vaccination policy is to offer future COVID-19 booster doses to individuals at high risk of serious illness from COVID-19, but it is still uncertain which groups of the population could benefit most. In response to an urgent request from the UK Joint Committee on Vaccination and Immunisation, we aimed to identify risk factors for severe COVID-19 outcomes (ie, COVID-19-related hospitalisation or death) in individuals who had completed their primary COVID-19 vaccination schedule and had received the first booster vaccine.We constructed prospective cohorts across all four UK nations through linkages of primary care, RT-PCR testing, vaccination, hospitalisation, and mortality data on 30 million people. We included individuals who received primary vaccine doses of BNT162b2 (tozinameran; Pfizer-BioNTech) or ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines in our initial analyses. We then restricted analyses to those given a BNT162b2 or mRNA-1273 (elasomeran; Moderna) booster and had a severe COVID-19 outcome between Dec 20, 2021, and Feb 28, 2022 (when the omicron (B.1.1.529) variant was dominant). We fitted time-dependent Poisson regression models and calculated adjusted rate ratios (aRRs) and 95% CIs for the associations between risk factors and COVID-19-related hospitalisation or death. We adjusted for a range of potential covariates, including age, sex, comorbidities, and previous SARS-CoV-2 infection. Stratified analyses were conducted by vaccine type. We then did pooled analyses across UK nations using fixed-effect meta-analyses.METHODSWe constructed prospective cohorts across all four UK nations through linkages of primary care, RT-PCR testing, vaccination, hospitalisation, and mortality data on 30 million people. We included individuals who received primary vaccine doses of BNT162b2 (tozinameran; Pfizer-BioNTech) or ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines in our initial analyses. We then restricted analyses to those given a BNT162b2 or mRNA-1273 (elasomeran; Moderna) booster and had a severe COVID-19 outcome between Dec 20, 2021, and Feb 28, 2022 (when the omicron (B.1.1.529) variant was dominant). We fitted time-dependent Poisson regression models and calculated adjusted rate ratios (aRRs) and 95% CIs for the associations between risk factors and COVID-19-related hospitalisation or death. We adjusted for a range of potential covariates, including age, sex, comorbidities, and previous SARS-CoV-2 infection. Stratified analyses were conducted by vaccine type. We then did pooled analyses across UK nations using fixed-effect meta-analyses.Between Dec 8, 2020, and Feb 28, 2022, 16 208 600 individuals completed their primary vaccine schedule and 13 836 390 individuals received a booster dose. Between Dec 20, 2021, and Feb 28, 2022, 59 510 (0·4%) of the primary vaccine group and 26 100 (0·2%) of those who received their booster had severe COVID-19 outcomes. The risk of severe COVID-19 outcomes reduced after receiving the booster (rate change: 8·8 events per 1000 person-years to 7·6 events per 1000 person-years). Older adults (≥80 years vs 18-49 years; aRR 3·60 [95% CI 3·45-3·75]), those with comorbidities (≥5 comorbidities vs none; 9·51 [9·07-9·97]), being male (male vs female; 1·23 [1·20-1·26]), and those with certain underlying health conditions-in particular, individuals receiving immunosuppressants (yes vs no; 5·80 [5·53-6·09])-and those with chronic kidney disease (stage 5 vs no; 3·71 [2·90-4·74]) remained at high risk despite the initial booster. Individuals with a history of COVID-19 infection were at reduced risk (infected ≥9 months before booster dose vs no previous infection; aRR 0·41 [95% CI 0·29-0·58]).FINDINGSBetween Dec 8, 2020, and Feb 28, 2022, 16 208 600 individuals completed their primary vaccine schedule and 13 836 390 individuals received a booster dose. Between Dec 20, 2021, and Feb 28, 2022, 59 510 (0·4%) of the primary vaccine group and 26 100 (0·2%) of those who received their booster had severe COVID-19 outcomes. The risk of severe COVID-19 outcomes reduced after receiving the booster (rate change: 8·8 events per 1000 person-years to 7·6 events per 1000 person-years). Older adults (≥80 years vs 18-49 years; aRR 3·60 [95% CI 3·45-3·75]), those with comorbidities (≥5 comorbidities vs none; 9·51 [9·07-9·97]), being male (male vs female; 1·23 [1·20-1·26]), and those with certain underlying health conditions-in particular, individuals receiving immunosuppressants (yes vs no; 5·80 [5·53-6·09])-and those with chronic kidney disease (stage 5 vs no; 3·71 [2·90-4·74]) remained at high risk despite the initial booster. Individuals with a history of COVID-19 infection were at reduced risk (infected ≥9 months before booster dose vs no previous infection; aRR 0·41 [95% CI 0·29-0·58]).Older people, those with multimorbidity, and those with specific underlying health conditions remain at increased risk of COVID-19 hospitalisation and death after the initial vaccine booster and should, therefore, be prioritised for additional boosters, including novel optimised versions, and the increasing array of COVID-19 therapeutics.INTERPRETATIONOlder people, those with multimorbidity, and those with specific underlying health conditions remain at increased risk of COVID-19 hospitalisation and death after the initial vaccine booster and should, therefore, be prioritised for additional boosters, including novel optimised versions, and the increasing array of COVID-19 therapeutics.National Core Studies-Immunity, UK Research and Innovation (Medical Research Council), Health Data Research UK, the Scottish Government, and the University of Edinburgh.FUNDINGNational Core Studies-Immunity, UK Research and Innovation (Medical Research Council), Health Data Research UK, the Scottish Government, and the University of Edinburgh. Current UK vaccination policy is to offer future COVID-19 booster doses to individuals at high risk of serious illness from COVID-19, but it is still uncertain which groups of the population could benefit most. In response to an urgent request from the UK Joint Committee on Vaccination and Immunisation, we aimed to identify risk factors for severe COVID-19 outcomes (ie, COVID-19-related hospitalisation or death) in individuals who had completed their primary COVID-19 vaccination schedule and had received the first booster vaccine. We constructed prospective cohorts across all four UK nations through linkages of primary care, RT-PCR testing, vaccination, hospitalisation, and mortality data on 30 million people. We included individuals who received primary vaccine doses of BNT162b2 (tozinameran; Pfizer-BioNTech) or ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines in our initial analyses. We then restricted analyses to those given a BNT162b2 or mRNA-1273 (elasomeran; Moderna) booster and had a severe COVID-19 outcome between Dec 20, 2021, and Feb 28, 2022 (when the omicron (B.1.1.529) variant was dominant). We fitted time-dependent Poisson regression models and calculated adjusted rate ratios (aRRs) and 95% CIs for the associations between risk factors and COVID-19-related hospitalisation or death. We adjusted for a range of potential covariates, including age, sex, comorbidities, and previous SARS-CoV-2 infection. Stratified analyses were conducted by vaccine type. We then did pooled analyses across UK nations using fixed-effect meta-analyses. Between Dec 8, 2020, and Feb 28, 2022, 16 208 600 individuals completed their primary vaccine schedule and 13 836 390 individuals received a booster dose. Between Dec 20, 2021, and Feb 28, 2022, 59 510 (0·4%) of the primary vaccine group and 26 100 (0·2%) of those who received their booster had severe COVID-19 outcomes. The risk of severe COVID-19 outcomes reduced after receiving the booster (rate change: 8·8 events per 1000 person-years to 7·6 events per 1000 person-years). Older adults (≥80 years vs 18-49 years; aRR 3·60 [95% CI 3·45-3·75]), those with comorbidities (≥5 comorbidities vs none; 9·51 [9·07-9·97]), being male (male vs female; 1·23 [1·20-1·26]), and those with certain underlying health conditions-in particular, individuals receiving immunosuppressants (yes vs no; 5·80 [5·53-6·09])-and those with chronic kidney disease (stage 5 vs no; 3·71 [2·90-4·74]) remained at high risk despite the initial booster. Individuals with a history of COVID-19 infection were at reduced risk (infected ≥9 months before booster dose vs no previous infection; aRR 0·41 [95% CI 0·29-0·58]). Older people, those with multimorbidity, and those with specific underlying health conditions remain at increased risk of COVID-19 hospitalisation and death after the initial vaccine booster and should, therefore, be prioritised for additional boosters, including novel optimised versions, and the increasing array of COVID-19 therapeutics. National Core Studies-Immunity, UK Research and Innovation (Medical Research Council), Health Data Research UK, the Scottish Government, and the University of Edinburgh. Current UK vaccination policy is to offer future COVID-19 booster doses to individuals at high risk of serious illness from COVID-19, but it is still uncertain which groups of the population could benefit most. In response to an urgent request from the UK Joint Committee on Vaccination and Immunisation, we aimed to identify risk factors for severe COVID-19 outcomes (ie, COVID-19-related hospitalisation or death) in individuals who had completed their primary COVID-19 vaccination schedule and had received the first booster vaccine. We constructed prospective cohorts across all four UK nations through linkages of primary care, RT-PCR testing, vaccination, hospitalisation, and mortality data on 30 million people. We included individuals who received primary vaccine doses of BNT162b2 (tozinameran; Pfizer–BioNTech) or ChAdOx1 nCoV-19 (Oxford–AstraZeneca) vaccines in our initial analyses. We then restricted analyses to those given a BNT162b2 or mRNA-1273 (elasomeran; Moderna) booster and had a severe COVID-19 outcome between Dec 20, 2021, and Feb 28, 2022 (when the omicron (B.1.1.529) variant was dominant). We fitted time-dependent Poisson regression models and calculated adjusted rate ratios (aRRs) and 95% CIs for the associations between risk factors and COVID-19-related hospitalisation or death. We adjusted for a range of potential covariates, including age, sex, comorbidities, and previous SARS-CoV-2 infection. Stratified analyses were conducted by vaccine type. We then did pooled analyses across UK nations using fixed-effect meta-analyses. Between Dec 8, 2020, and Feb 28, 2022, 17 337 580 individuals completed their primary vaccine schedule and 14 698 030 individuals received a booster dose. Between Dec 20, 2021, and Feb 28, 2022, 59 510 (0·3%) of the primary vaccine group and 26 100 (0·2%) of those who received their booster had severe COVID-19 outcomes. The risk of severe COVID-19 outcomes reduced after receiving the booster (rate change: 8·8 events per 1000 person-years to 7·6 events per 1000 person-years). Older adults (≥80 years vs 18–49 years; aRR 3·60 [95% CI 3·45–3·75]), those with comorbidities (≥5 comorbidities vs none; 9·51 [9·07–9·97]), being male (male vs female; 1·23 [1·20–1·26]), and those with certain underlying health conditions—in particular, individuals receiving immunosuppressants (yes vs no; 5·80 [5·53–6·09])—and those with chronic kidney disease (stage 5 vs no; 3·71 [2·90–4·74]) remained at high risk despite the initial booster. Individuals with a history of COVID-19 infection were at reduced risk (infected ≥9 months before booster dose vs no previous infection; aRR 0·41 [95% CI 0·29–0·58]). Older people, those with multimorbidity, and those with specific underlying health conditions remain at increased risk of COVID-19 hospitalisation and death after the initial vaccine booster and should, therefore, be prioritised for additional boosters, including novel optimised versions, and the increasing array of COVID-19 therapeutics. National Core Studies–Immunity, UK Research and Innovation (Medical Research Council), Health Data Research UK, the Scottish Government, and the University of Edinburgh. Summary Background Current UK vaccination policy is to offer future COVID-19 booster doses to individuals at high risk of serious illness from COVID-19, but it is still uncertain which groups of the population could benefit most. In response to an urgent request from the UK Joint Committee on Vaccination and Immunisation, we aimed to identify risk factors for severe COVID-19 outcomes (ie, COVID-19-related hospitalisation or death) in individuals who had completed their primary COVID-19 vaccination schedule and had received the first booster vaccine. Methods We constructed prospective cohorts across all four UK nations through linkages of primary care, RT-PCR testing, vaccination, hospitalisation, and mortality data on 30 million people. We included individuals who received primary vaccine doses of BNT162b2 (tozinameran; Pfizer–BioNTech) or ChAdOx1 nCoV-19 (Oxford–AstraZeneca) vaccines in our initial analyses. We then restricted analyses to those given a BNT162b2 or mRNA-1273 (elasomeran; Moderna) booster and had a severe COVID-19 outcome between Dec 20, 2021, and Feb 28, 2022 (when the omicron (B.1.1.529) variant was dominant). We fitted time-dependent Poisson regression models and calculated adjusted rate ratios (aRRs) and 95% CIs for the associations between risk factors and COVID-19-related hospitalisation or death. We adjusted for a range of potential covariates, including age, sex, comorbidities, and previous SARS-CoV-2 infection. Stratified analyses were conducted by vaccine type. We then did pooled analyses across UK nations using fixed-effect meta-analyses. Findings Between Dec 8, 2020, and Feb 28, 2022, 16 208 600 individuals completed their primary vaccine schedule and 13 836 390 individuals received a booster dose. Between Dec 20, 2021, and Feb 28, 2022, 59 510 (0·4%) of the primary vaccine group and 26 100 (0·2%) of those who received their booster had severe COVID-19 outcomes. The risk of severe COVID-19 outcomes reduced after receiving the booster (rate change: 8·8 events per 1000 person-years to 7·6 events per 1000 person-years). Older adults (≥80 years vs 18–49 years; aRR 3·60 [95% CI 3·45–3·75]), those with comorbidities (≥5 comorbidities vs none; 9·51 [9·07–9·97]), being male (male vs female; 1·23 [1·20–1·26]), and those with certain underlying health conditions—in particular, individuals receiving immunosuppressants (yes vs no; 5·80 [5·53–6·09])—and those with chronic kidney disease (stage 5 vs no; 3·71 [2·90–4·74]) remained at high risk despite the initial booster. Individuals with a history of COVID-19 infection were at reduced risk (infected ≥9 months before booster dose vs no previous infection; aRR 0·41 [95% CI 0·29–0·58]). Interpretation Older people, those with multimorbidity, and those with specific underlying health conditions remain at increased risk of COVID-19 hospitalisation and death after the initial vaccine booster and should, therefore, be prioritised for additional boosters, including novel optimised versions, and the increasing array of COVID-19 therapeutics. Funding National Core Studies–Immunity, UK Research and Innovation (Medical Research Council), Health Data Research UK, the Scottish Government, and the University of Edinburgh.
Author	Bedston, Stuart McCowan, Colin Simpson, Colin R Katikireddi, Srinivasa Vittal Owen, Rhiannon K Akbari, Ashley Murphy, Siobhán Bradley, Declan T Shah, Syed Ahmar O'Reilly, Dermot Oke, Jason Azcoaga-Lorenzo, Amaya Lyons, Ronan A Fagbamigbe, Adeniyi Francis Sheikh, Aziz Rudan, Igor Hall, Elliott C R Kerr, Steven Joy, Mark Torabi, Fatemeh Grange, Zoe Tsang, Ruby S M Ritchie, Lewis Robertson, Chris de Lusignan, Simon Patterson, Lynsey Agrawal, Utkarsh
Author_xml	– sequence: 1 givenname: Utkarsh surname: Agrawal fullname: Agrawal, Utkarsh organization: School of Medicine, University of St Andrews, St Andrews, UK – sequence: 2 givenname: Stuart surname: Bedston fullname: Bedston, Stuart organization: Population Data Science, Swansea University Medical School, Faculty of Medicine, Health, and Life Science, Swansea University, Swansea, UK – sequence: 3 givenname: Colin surname: McCowan fullname: McCowan, Colin organization: School of Medicine, University of St Andrews, St Andrews, UK – sequence: 4 givenname: Jason surname: Oke fullname: Oke, Jason organization: Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK – sequence: 5 givenname: Lynsey surname: Patterson fullname: Patterson, Lynsey organization: Centre for Public Health, Queen's University Belfast, Belfast, UK – sequence: 6 givenname: Chris surname: Robertson fullname: Robertson, Chris organization: Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK – sequence: 7 givenname: Ashley surname: Akbari fullname: Akbari, Ashley organization: Population Data Science, Swansea University Medical School, Faculty of Medicine, Health, and Life Science, Swansea University, Swansea, UK – sequence: 8 givenname: Amaya surname: Azcoaga-Lorenzo fullname: Azcoaga-Lorenzo, Amaya organization: School of Medicine, University of St Andrews, St Andrews, UK – sequence: 9 givenname: Declan T surname: Bradley fullname: Bradley, Declan T organization: Centre for Public Health, Queen's University Belfast, Belfast, UK – sequence: 10 givenname: Adeniyi Francis surname: Fagbamigbe fullname: Fagbamigbe, Adeniyi Francis organization: School of Medicine, University of St Andrews, St Andrews, UK – sequence: 11 givenname: Zoe surname: Grange fullname: Grange, Zoe organization: Public Health Scotland, Glasgow, UK – sequence: 12 givenname: Elliott C R surname: Hall fullname: Hall, Elliott C R organization: Public Health Scotland, Glasgow, UK – sequence: 13 givenname: Mark surname: Joy fullname: Joy, Mark organization: Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK – sequence: 14 givenname: Srinivasa Vittal surname: Katikireddi fullname: Katikireddi, Srinivasa Vittal organization: MRC/CSO Social & Public Health Sciences Unit, University of Glasgow, Glasgow, UK – sequence: 15 givenname: Steven surname: Kerr fullname: Kerr, Steven organization: Usher Institute, University of Edinburgh, Edinburgh, UK – sequence: 16 givenname: Lewis surname: Ritchie fullname: Ritchie, Lewis organization: Academic Primary Care, University of Aberdeen School of Medicine and Dentistry, Aberdeen, UK – sequence: 17 givenname: Siobhán surname: Murphy fullname: Murphy, Siobhán organization: Centre for Public Health, Queen's University Belfast, Belfast, UK – sequence: 18 givenname: Rhiannon K surname: Owen fullname: Owen, Rhiannon K organization: Population Data Science, Swansea University Medical School, Faculty of Medicine, Health, and Life Science, Swansea University, Swansea, UK – sequence: 19 givenname: Igor surname: Rudan fullname: Rudan, Igor organization: Centre of Global Health, Usher Institute, University of Edinburgh, Edinburgh, UK – sequence: 20 givenname: Syed Ahmar surname: Shah fullname: Shah, Syed Ahmar organization: Usher Institute, University of Edinburgh, Edinburgh, UK – sequence: 21 givenname: Colin R surname: Simpson fullname: Simpson, Colin R organization: Usher Institute, University of Edinburgh, Edinburgh, UK – sequence: 22 givenname: Fatemeh surname: Torabi fullname: Torabi, Fatemeh organization: Population Data Science, Swansea University Medical School, Faculty of Medicine, Health, and Life Science, Swansea University, Swansea, UK – sequence: 23 givenname: Ruby S M surname: Tsang fullname: Tsang, Ruby S M organization: Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK – sequence: 24 givenname: Simon surname: de Lusignan fullname: de Lusignan, Simon organization: Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK – sequence: 25 givenname: Ronan A surname: Lyons fullname: Lyons, Ronan A organization: Population Data Science, Swansea University Medical School, Faculty of Medicine, Health, and Life Science, Swansea University, Swansea, UK – sequence: 26 givenname: Dermot surname: O'Reilly fullname: O'Reilly, Dermot organization: Centre for Public Health, Queen's University Belfast, Belfast, UK – sequence: 27 givenname: Aziz surname: Sheikh fullname: Sheikh, Aziz email: aziz.sheikh@ed.ac.uk organization: Usher Institute, University of Edinburgh, Edinburgh, UK
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/36244382$$D View this record in MEDLINE/PubMed
BookMark	eNqNUk1v1DAQjVAR3RZ-AsgSlyIRcBzH2QUBQkuBShU9LF83y7EnXbdee7GdSPtf-TE4m20FeykHy9bMe2_GM-8oO7DOQpY9LvCLAhfs5QIXFOesLtkJIc9SpGJ5fS-bFLSmeUXrnwfZ5BZymB2FcIUxpgxXD7LDkhFKyymZZL8X0IMHNL_4fvYhL2bIdVG6FQQk2ggetZ0xqBdSaiuidha5Fq29Xgm_QUEuQXUGkLAKaaujFgY1zoVEDK_Q2jkDKiWF2QQdBuaokVBr78IaZNQ9IOmWzkcUYqc0bGElRittzFBOW6V7rTphQnqjU3tpUrXn6EuiLMFbdOZhjCyki-NraOeHMBAeZvfbRIRHu_s4-_bx9Ov8c35-8els_v48l6yoYk4xqwlAQ5VqsKQNhilupKQtYW1Zi3QaBaQFRgluKjEVrKFyShWepSlWU1YeZ29H3XXXrEBJsNELw3dz4k5o_m_G6iW_dD2fVQzXdBA42Ql496uDEPlKBwkm_QdcFzipSZVKUTxN0Kd70CvX-TTTLYpWMzIjg-CTvzu6beVm8QnwegTItIngoeVSx-12UoPa8ALzwWZ8azM-eIgTwrc243ViV3vsmwJ38d6NPEjb6DV4HqQGK0Fpn9zAldN3KrzZU5AmWU8Kcw2b_-D_ASdmAhc
CitedBy_id	crossref_primary_10_1016_j_jinf_2024_01_009 crossref_primary_10_1016_S0140_6736_24_02560_1 crossref_primary_10_3389_fimmu_2025_1597333 crossref_primary_10_1093_cid_ciad546 crossref_primary_10_1016_j_vaccine_2025_126853 crossref_primary_10_1093_ageing_afad204 crossref_primary_10_1016_j_ijid_2024_107084 crossref_primary_10_1093_cid_ciae510 crossref_primary_10_1136_bmjopen_2023_075518 crossref_primary_10_1016_S1473_3099_23_00736_3 crossref_primary_10_1016_S2665_9913_23_00160_1 crossref_primary_10_1038_s41467_024_46451_0 crossref_primary_10_1016_j_jiph_2025_102746 crossref_primary_10_1016_j_puhe_2024_03_015 crossref_primary_10_1038_s41598_023_47130_8 crossref_primary_10_1038_s41541_024_00898_w crossref_primary_10_1016_j_ccm_2024_10_008 crossref_primary_10_1016_j_gene_2024_148970 crossref_primary_10_1093_ndt_gfad170 crossref_primary_10_3390_medicina59020202 crossref_primary_10_2196_44822 crossref_primary_10_1186_s41231_024_00167_x crossref_primary_10_1016_S1473_3099_22_00688_0 crossref_primary_10_2196_52047 crossref_primary_10_1016_S0140_6736_25_00098_4 crossref_primary_10_1136_bmjopen_2023_071607 crossref_primary_10_1126_scitranslmed_adk1599 crossref_primary_10_3390_biomedicines11010117 crossref_primary_10_3389_fmed_2024_1344267 crossref_primary_10_1016_j_eclinm_2025_103114 crossref_primary_10_1093_oncolo_oyaf074 crossref_primary_10_3389_fcimb_2023_1207313 crossref_primary_10_3389_fpubh_2023_1227935 crossref_primary_10_3390_v17010038 crossref_primary_10_1016_j_vaccine_2023_01_067 crossref_primary_10_1038_s41598_024_68592_4 crossref_primary_10_1097_CP9_0000000000000043 crossref_primary_10_3389_fimmu_2023_1296148 crossref_primary_10_1136_bmj_2023_076810 crossref_primary_10_1016_j_jmii_2023_12_003 crossref_primary_10_1007_s40121_024_01100_3 crossref_primary_10_3390_vaccines12091018 crossref_primary_10_7189_jogh_13_06042 crossref_primary_10_1007_s40472_023_00410_8 crossref_primary_10_1016_j_jinf_2023_08_014 crossref_primary_10_1016_j_coi_2023_102390 crossref_primary_10_1038_s41598_023_47043_6 crossref_primary_10_1016_j_jamda_2023_11_027 crossref_primary_10_1164_rccm_202401_0145OC crossref_primary_10_1159_000530566 crossref_primary_10_1055_s_0043_1777769 crossref_primary_10_3390_cells12222601 crossref_primary_10_1016_j_jtha_2023_09_033 crossref_primary_10_3390_ijerph20042779 crossref_primary_10_1007_s10157_024_02560_0 crossref_primary_10_1002_iid3_1259 crossref_primary_10_1038_s41598_024_61922_6 crossref_primary_10_1136_bmjph_2023_000770 crossref_primary_10_1007_s10654_023_00965_x crossref_primary_10_17533_udea_iatreia_338 crossref_primary_10_3389_fpubh_2023_1207679 crossref_primary_10_1016_j_chest_2024_07_155 crossref_primary_10_1136_rmdopen_2022_002871 crossref_primary_10_1016_j_jinf_2024_106129 crossref_primary_10_1093_rap_rkad097 crossref_primary_10_1016_j_cmi_2023_03_026 crossref_primary_10_1016_j_idnow_2025_105058 crossref_primary_10_1186_s12879_025_10585_3 crossref_primary_10_1016_S1473_3099_23_00272_4 crossref_primary_10_1016_S2213_2600_23_00435_6 crossref_primary_10_1111_1756_185X_15251 crossref_primary_10_1007_s15010_025_02583_z crossref_primary_10_1016_j_puhip_2024_100494 crossref_primary_10_3390_microorganisms13030641 crossref_primary_10_1016_j_cmi_2023_04_014 crossref_primary_10_1016_j_ijid_2024_107161 crossref_primary_10_1097_MD_0000000000036777 crossref_primary_10_3390_jcm12134517 crossref_primary_10_2196_52134 crossref_primary_10_15585_mmwr_mm7303a2 crossref_primary_10_3390_vaccines12020199 crossref_primary_10_1016_S0140_6736_22_01971_7 crossref_primary_10_3389_fcimb_2023_1141274 crossref_primary_10_1007_s10238_024_01388_y crossref_primary_10_1093_qjmed_hcad236 crossref_primary_10_1371_journal_pone_0283447 crossref_primary_10_1001_jamanetworkopen_2024_0288 crossref_primary_10_1371_journal_pone_0300306 crossref_primary_10_3389_fpubh_2023_1194349 crossref_primary_10_1016_S0140_6736_23_00443_9 crossref_primary_10_1371_journal_pone_0329701 crossref_primary_10_1038_s41467_023_44276_x crossref_primary_10_2196_56042 crossref_primary_10_1016_S1473_3099_23_00207_4 crossref_primary_10_1097_EDE_0000000000001747 crossref_primary_10_1016_S2213_2600_24_00151_6 crossref_primary_10_1080_20477724_2025_2554138 crossref_primary_10_1016_j_msard_2023_104548 crossref_primary_10_2147_IDR_S397231 crossref_primary_10_3389_fpubh_2024_1338208 crossref_primary_10_1016_j_clinthera_2025_07_006 crossref_primary_10_1093_qjmed_hcad106 crossref_primary_10_3390_v15071449 crossref_primary_10_1016_j_vaccine_2023_01_023 crossref_primary_10_1007_s12325_024_03043_0 crossref_primary_10_1111_tid_14168 crossref_primary_10_1016_j_isci_2025_111837 crossref_primary_10_1016_S0140_6736_23_01180_7 crossref_primary_10_7759_cureus_80582 crossref_primary_10_3390_vaccines13060566 crossref_primary_10_1111_bjh_18714 crossref_primary_10_1038_s41591_023_02414_4 crossref_primary_10_4009_jsdt_58_323 crossref_primary_10_1016_S0140_6736_23_00444_0 crossref_primary_10_1177_1358863X231224383 crossref_primary_10_1016_j_vaccine_2024_01_012 crossref_primary_10_1093_ofid_ofad330 crossref_primary_10_1007_s15010_023_02169_7 crossref_primary_10_1080_07853890_2024_2313062 crossref_primary_10_7189_jogh_14_05027 crossref_primary_10_1136_bmjopen_2023_077675 crossref_primary_10_1016_j_eclinm_2025_103449 crossref_primary_10_3390_v16030351 crossref_primary_10_3390_v16040488 crossref_primary_10_1016_j_ebiom_2023_104552 crossref_primary_10_1080_14760584_2024_2402955 crossref_primary_10_1016_S1473_3099_23_00122_6 crossref_primary_10_3389_fimmu_2025_1501666 crossref_primary_10_1055_a_1962_4238 crossref_primary_10_1080_22221751_2023_2169197 crossref_primary_10_1093_eurheartj_ehae335 crossref_primary_10_1016_j_vaccine_2024_126221 crossref_primary_10_1097_MCP_0000000000000948 crossref_primary_10_3390_vaccines10122118 crossref_primary_10_1016_j_vaccine_2023_10_029 crossref_primary_10_1001_jamainternmed_2023_3033 crossref_primary_10_1080_21645515_2024_2322795 crossref_primary_10_1186_s12889_024_17790_w crossref_primary_10_1093_ndt_gfad262
Cites_doi	10.1056/NEJMc2202542 10.1056/NEJMoa2115624 10.1016/S0140-6736(21)02754-9 10.1056/NEJMoa2116063 10.1371/journal.pmed.1001885 10.1186/1472-6947-9-3 10.1016/S0140-6736(22)00090-3 10.1016/S2213-8587(22)00158-9 10.1016/S0140-6736(21)00677-2 10.1016/S1473-3099(22)00141-4 10.1016/S0140-6736(21)02718-5 10.1016/S2213-2600(21)00380-5 10.1056/NEJMoa2114583 10.1002/jrsm.12 10.1001/jama.2022.0210 10.1186/1472-6963-9-157 10.2139/ssrn.3910058 10.2196/preprints.39141 10.1016/S0140-6736(07)61602-X 10.1056/NEJMoa2114255 10.1016/S0140-6736(21)00501-8 10.1016/S0140-6736(21)02249-2 10.1093/ije/dyab028 10.1056/NEJMoa2118691
ContentType	Journal Article
Copyright	2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. 2022. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2022
Copyright_xml	– notice: 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license – notice: Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. – notice: 2022. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2022
DBID	6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U S0X 7X8 5PM
DOI	10.1016/S0140-6736(22)01656-7
DatabaseName	ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland British Nursing Database British Nursing Index ProQuest Central Essentials Biological Science Collection eLibrary ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central British Nursing Index (BNI) (1985 to Present) Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium British Nursing Index Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional Biological Sciences Consumer Health Database Health & Medical Collection (Alumni Edition) Healthcare Administration Database Medical Database Psychology Database ProQuest Research Library Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic SIRS Editorial MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE ProQuest One Psychology
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1474-547X
EndPage	1320
ExternalDocumentID	PMC9560746 36244382 10_1016_S0140_6736_22_01656_7 S0140673622016567
Genre	Journal Article
GeographicLocations	England Scotland Northern Ireland Wales Israel United Kingdom--UK
GeographicLocations_xml	– name: England – name: Northern Ireland – name: Wales – name: Scotland – name: Israel – name: United Kingdom--UK
GrantInformation	National Core Studies-Immunity, UK Research and Innovation (Medical Research Council), Health Data Research UK, the Scottish Government, and the University of Edinburgh.
GrantInformation_xml	– fundername: Chief Scientist Office grantid: SPHSU17 – fundername: Medical Research Council grantid: MC_PC_20060 – fundername: Medical Research Council grantid: MR/R008345/1 – fundername: Medical Research Council grantid: MR/V028367/1 – fundername: Chief Scientist Office grantid: SCAF/15/02 – fundername: Medical Research Council grantid: MC_PC_19075 – fundername: Medical Research Council grantid: MR/W014386/1 – fundername: Medical Research Council grantid: MC_UU_00022/2 – fundername: Medical Research Council grantid: MC_PC_19004 – fundername: Medical Research Council grantid: MC_PC_20058
GroupedDBID	--- --K --M .1- .55 .CO .FO 0R~ 123 1B1 1P~ 1RT 1~5 29L 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 9JM AABNK AAEDT AAEDW AAFWJ AAIKJ AAKOC AALRI AAMRU AAQFI AATTM AAXKI AAXUO AAYWO ABBQC ABCQX ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOCM ABUFD ABUWG ACGFS ACGOD ACIEU ACIUM ACLOT ACPRK ACRLP ACVFH ADBBV ADCNI AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGAPS AGHFR AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EAU EBS EFJIC EFKBS EO8 EO9 EP2 EP3 EWM EX3 F5P FD8 FDB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K-O K9- KOM L7B LK8 LZ2 M0R M0T M1P M2M M2O M2P M7P MJL MO0 N9A NAPCQ O-L O9- OD. OO~ OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PRG PROAC PSQYO PSYQQ ROL RPZ S0X SAD SDG SEL SES SJFOW SJN SPCBC SSH SSZ T5K TLN TWZ UAP UBE UKHRP UV1 WOW X7M XAX XDU YYM Z5R ZMT ~HD 6I. AACTN AAFTH AFCTW ALIPV M41 .GJ 04C 3EH 3O- 41~ 8WZ 9DU A6W AAEJM AAKAS AAQQT AAQXK AAYXX ABDBF ABWVN ACRPL ACUHS ADMUD ADNMO ADXHL ADZCM AFFHD AFFNX AGQPQ AHHHB AHQJS AJJEV AKVCP ARTTT ASPBG AVWKF AZFZN CITATION D0S EAP EAS EAZ EBC EBD EBU EGS EHN EIHBH EJD EMB EMK EMOBN ENC EPL EPS EPT ESX EVS FEDTE FGOYB HVGLF HZ~ J5H MVM OVD Q~Q R2- SV3 TEORI TH9 UHU UQL WOQ WUQ XPP YYQ ZGI ZXP ZY4 ~G0 AGCQF AGRNS CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7TK 7U7 7U9 7XB 88A 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c615t-40672eeb4ddb0c4b0e80bcc4f26f37af37bde2fe6420b5a8a6b4c84d092445863
IEDL.DBID	M7P
ISICitedReferencesCount	157
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000898605000022&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0140-6736 1474-547X
IngestDate	Tue Nov 04 02:07:12 EST 2025 Thu Oct 02 06:15:30 EDT 2025 Tue Oct 07 07:09:28 EDT 2025 Mon Jul 21 06:08:03 EDT 2025 Tue Nov 18 22:37:12 EST 2025 Sat Nov 29 07:25:20 EST 2025 Sun Apr 06 06:53:32 EDT 2025 Tue Oct 14 19:30:50 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	10360
Language	English
License	This is an open access article under the CC BY license. Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c615t-40672eeb4ddb0c4b0e80bcc4f26f37af37bde2fe6420b5a8a6b4c84d092445863
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Contributed equally
OpenAccessLink	https://pubmed.ncbi.nlm.nih.gov/PMC9560746
PMID	36244382
PQID	2724592926
PQPubID	40246
PageCount	16
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_9560746 proquest_miscellaneous_2725445408 proquest_journals_2724592926 pubmed_primary_36244382 crossref_citationtrail_10_1016_S0140_6736_22_01656_7 crossref_primary_10_1016_S0140_6736_22_01656_7 elsevier_sciencedirect_doi_10_1016_S0140_6736_22_01656_7 elsevier_clinicalkey_doi_10_1016_S0140_6736_22_01656_7
PublicationCentury	2000
PublicationDate	2022-10-15
PublicationDateYYYYMMDD	2022-10-15
PublicationDate_xml	– month: 10 year: 2022 text: 2022-10-15 day: 15
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England – name: London
PublicationTitle	The Lancet (British edition)
PublicationTitleAlternate	Lancet
PublicationYear	2022
Publisher	Elsevier Ltd Elsevier Limited The Author(s). Published by Elsevier Ltd
Publisher_xml	– name: Elsevier Ltd – name: Elsevier Limited – name: The Author(s). Published by Elsevier Ltd
References	Barda, Dagan, Cohen (bib8) 2021; 398 Agrawal, Katikireddi, McCowan (bib23) 2021; 9 Vasileiou, Simpson, Shi (bib25) 2021; 397 Kearns, Siebert, Gaskell (bib35) 2021 Leston M, Elson WH, Watson C, et al. Representativeness, vaccination uptake and COVID clinical outcomes 2020–21 in the UK's Oxford-RCGP Research and Surveillance Network: cohort profile. (bib12) 2022 Borenstein, Hedges, Higgins, Rothstein (bib24) 2010; 1 Arbel, Hammerman, Sergienko (bib9) 2021; 385 (bib5) 2022 Clift, Coupland, Keogh (bib16) 2020; 371 Benchimol, Smeeth, Guttmann (bib14) 2015; 12 (bib1) 2021 (bib11) 2022 Kuhlmann, Mayer, Claassen (bib6) 2022; 399 Levin, Lustig, Cohen (bib33) 2021; 385 (bib13) 2020 Bar-On, Goldberg, Mandel (bib7) 2021; 385 Stuart, Shaw, Liu (bib29) 2022; 399 Mulholland, Vasileiou, Simpson (bib18) 2021; 50 (in press). von Elm, Altman, Egger, Pocock, Gøtzsche, Vandenbroucke (bib15) 2007; 370 Ford, Jones, Verplancke (bib20) 2009; 9 Wang, Davis, Kaelber, Volkow, Xu (bib32) 2022; 327 Lyons, Jones, John (bib19) 2009; 9 Manisty, Otter, Treibel (bib31) 2021; 397 (bib21) 2017 (bib2) 2022 (bib22) 2019 Wise (bib3) 2021; 374 Hall, Foulkes, Insalata (bib30) 2022; 386 Piernas, Patone, Astbury (bib26) 2022; 10 Rosenberg, Dorabawila, Easton (bib27) 2022; 386 Regev-Yochay, Gonen, Gilboa (bib34) 2022; 386 Sheikh, Kerr, Woolhouse (bib4) 2022; 22 Agrawal, Katikireddi, McCowan (bib10) 2021; 9 Katikireddi, Cerqueira-Silva, Vasileiou (bib28) 2022; 399 Wise (10.1016/S0140-6736(22)01656-7_bib3) 2021; 374 Sheikh (10.1016/S0140-6736(22)01656-7_bib4) 2022; 22 Katikireddi (10.1016/S0140-6736(22)01656-7_bib28) 2022; 399 Hall (10.1016/S0140-6736(22)01656-7_bib30) 2022; 386 Kuhlmann (10.1016/S0140-6736(22)01656-7_bib6) 2022; 399 Arbel (10.1016/S0140-6736(22)01656-7_bib9) 2021; 385 von Elm (10.1016/S0140-6736(22)01656-7_bib15) 2007; 370 Levin (10.1016/S0140-6736(22)01656-7_bib33) 2021; 385 Lyons (10.1016/S0140-6736(22)01656-7_bib19) 2009; 9 Kearns (10.1016/S0140-6736(22)01656-7_bib35) 2021 Agrawal (10.1016/S0140-6736(22)01656-7_bib23) 2021; 9 Vasileiou (10.1016/S0140-6736(22)01656-7_bib25) 2021; 397 Barda (10.1016/S0140-6736(22)01656-7_bib8) 2021; 398 Manisty (10.1016/S0140-6736(22)01656-7_bib31) 2021; 397 Rosenberg (10.1016/S0140-6736(22)01656-7_bib27) 2022; 386 Wang (10.1016/S0140-6736(22)01656-7_bib32) 2022; 327 Stuart (10.1016/S0140-6736(22)01656-7_bib29) 2022; 399 Clift (10.1016/S0140-6736(22)01656-7_bib16) 2020; 371 Regev-Yochay (10.1016/S0140-6736(22)01656-7_bib34) 2022; 386 Piernas (10.1016/S0140-6736(22)01656-7_bib26) 2022; 10 Agrawal (10.1016/S0140-6736(22)01656-7_bib10) 2021; 9 Ford (10.1016/S0140-6736(22)01656-7_bib20) 2009; 9 Borenstein (10.1016/S0140-6736(22)01656-7_bib24) 2010; 1 Bar-On (10.1016/S0140-6736(22)01656-7_bib7) 2021; 385 10.1016/S0140-6736(22)01656-7_bib17 Mulholland (10.1016/S0140-6736(22)01656-7_bib18) 2021; 50 Benchimol (10.1016/S0140-6736(22)01656-7_bib14) 2015; 12 38521559 - Lancet. 2024 Mar 23;403(10432):1140. doi: 10.1016/S0140-6736(24)00493-8. 37120280 - Lancet. 2023 Apr 29;401(10386):1423-1424. doi: 10.1016/S0140-6736(23)00443-9. 36244366 - Lancet. 2022 Oct 15;400(10360):1282-1283. doi: 10.1016/S0140-6736(22)01971-7.
References_xml	– year: 2022 ident: bib2 article-title: COVID-19: the green book, chapter 14a – year: 2022 ident: bib11 article-title: Interim statement on the use of additional booster doses of Emergency Use Listed mRNA vaccines against COVID-19 – volume: 12 year: 2015 ident: bib14 article-title: The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement publication-title: PLoS Med – volume: 50 start-page: 1064 year: 2021 end-page: 1074 ident: bib18 article-title: Cohort profile: Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) Database publication-title: Int J Epidemiol – year: 2019 ident: bib22 article-title: English indices of deprivation 2019 – volume: 9 start-page: 157 year: 2009 ident: bib20 article-title: The SAIL Databank: building a national architecture for e-health research and evaluation publication-title: BMC Health Serv Res – year: 2021 ident: bib1 article-title: Coronavirus (COVID-19) vaccinations – volume: 1 start-page: 97 year: 2010 end-page: 111 ident: bib24 article-title: A basic introduction to fixed-effect and random-effects models for meta-analysis publication-title: Res Synth Methods – volume: 371 year: 2020 ident: bib16 article-title: Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study publication-title: BMJ – volume: 386 start-page: 1377 year: 2022 end-page: 1380 ident: bib34 article-title: Efficacy of a fourth dose of COVID-19 mRNA vaccine against omicron publication-title: N Engl J Med – volume: 397 start-page: 1057 year: 2021 end-page: 1058 ident: bib31 article-title: Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals publication-title: Lancet – year: 2021 ident: bib35 article-title: Examining the immunological effects of COVID-19 vaccination in patients with conditions potentially leading to diminished immune response capacity–the OCTAVE trial publication-title: SSRN – volume: 9 start-page: 3 year: 2009 ident: bib19 article-title: The SAIL databank: linking multiple health and social care datasets publication-title: BMC Med Inform Decis Mak – year: 2020 ident: bib13 article-title: EAVE II – volume: 327 start-page: 678 year: 2022 end-page: 680 ident: bib32 article-title: Comparison of mRNA-1273 and BNT162b2 vaccines on breakthrough SARS-CoV-2 infections, hospitalizations, and death during the delta-predominant period publication-title: JAMA – volume: 385 start-page: 2413 year: 2021 end-page: 2420 ident: bib9 article-title: BNT162b2 vaccine booster and mortality due to COVID-19 publication-title: N Engl J Med – volume: 370 start-page: 1453 year: 2007 end-page: 1457 ident: bib15 article-title: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies publication-title: Lancet – volume: 386 start-page: 116 year: 2022 end-page: 127 ident: bib27 article-title: COVID-19 vaccine effectiveness in New York State publication-title: N Engl J Med – volume: 386 start-page: 1207 year: 2022 end-page: 1220 ident: bib30 article-title: Protection against SARS-CoV-2 after COVID-19 vaccination and previous infection publication-title: N Engl J Med – year: 2022 ident: bib5 article-title: How to get a booster dose of the coronavirus (COVID-19) vaccine – year: 2017 ident: bib21 article-title: Northern Ireland Multiple Deprivation Measure 2017 (NIMDM2017) – volume: 385 start-page: 1393 year: 2021 end-page: 1400 ident: bib7 article-title: Protection of BNT162b2 vaccine booster against Covid-19 in Israel publication-title: N Engl J Med – volume: 9 start-page: 1439 year: 2021 end-page: 1449 ident: bib10 article-title: COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study publication-title: Lancet Respir Med – volume: 10 start-page: 571 year: 2022 end-page: 580 ident: bib26 article-title: Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort study publication-title: Lancet Diabetes Endocrinol – volume: 397 start-page: 1646 year: 2021 end-page: 1657 ident: bib25 article-title: Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study publication-title: Lancet – volume: 399 start-page: 625 year: 2022 end-page: 626 ident: bib6 article-title: Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose publication-title: Lancet – reference: Leston M, Elson WH, Watson C, et al. Representativeness, vaccination uptake and COVID clinical outcomes 2020–21 in the UK's Oxford-RCGP Research and Surveillance Network: cohort profile. – volume: 385 start-page: e84 year: 2021 ident: bib33 article-title: Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months publication-title: N Engl J Med – volume: 398 start-page: 2093 year: 2021 end-page: 2100 ident: bib8 article-title: Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study publication-title: Lancet – volume: 399 start-page: 36 year: 2022 end-page: 49 ident: bib29 article-title: Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial publication-title: Lancet – volume: 22 start-page: 959 year: 2022 end-page: 966 ident: bib4 article-title: Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design publication-title: Lancet Infect Dis – volume: 374 year: 2021 ident: bib3 article-title: COVID-19: booster doses to be offered to 30 million people in UK publication-title: BMJ – year: 2022 ident: bib12 article-title: Vulnerable adults set for autumn COVID booster jab – reference: (in press). – volume: 9 start-page: 1439 year: 2021 end-page: 1449 ident: bib23 article-title: COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study publication-title: Lancet Respir Med – volume: 399 start-page: 25 year: 2022 end-page: 35 ident: bib28 article-title: Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil publication-title: Lancet – volume: 386 start-page: 1377 year: 2022 ident: 10.1016/S0140-6736(22)01656-7_bib34 article-title: Efficacy of a fourth dose of COVID-19 mRNA vaccine against omicron publication-title: N Engl J Med doi: 10.1056/NEJMc2202542 – volume: 385 start-page: 2413 year: 2021 ident: 10.1016/S0140-6736(22)01656-7_bib9 article-title: BNT162b2 vaccine booster and mortality due to COVID-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2115624 – volume: 399 start-page: 25 year: 2022 ident: 10.1016/S0140-6736(22)01656-7_bib28 article-title: Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil publication-title: Lancet doi: 10.1016/S0140-6736(21)02754-9 – volume: 386 start-page: 116 year: 2022 ident: 10.1016/S0140-6736(22)01656-7_bib27 article-title: COVID-19 vaccine effectiveness in New York State publication-title: N Engl J Med doi: 10.1056/NEJMoa2116063 – volume: 12 year: 2015 ident: 10.1016/S0140-6736(22)01656-7_bib14 article-title: The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement publication-title: PLoS Med doi: 10.1371/journal.pmed.1001885 – volume: 9 start-page: 3 year: 2009 ident: 10.1016/S0140-6736(22)01656-7_bib19 article-title: The SAIL databank: linking multiple health and social care datasets publication-title: BMC Med Inform Decis Mak doi: 10.1186/1472-6947-9-3 – volume: 399 start-page: 625 year: 2022 ident: 10.1016/S0140-6736(22)01656-7_bib6 article-title: Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose publication-title: Lancet doi: 10.1016/S0140-6736(22)00090-3 – volume: 10 start-page: 571 year: 2022 ident: 10.1016/S0140-6736(22)01656-7_bib26 article-title: Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort study publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(22)00158-9 – volume: 397 start-page: 1646 year: 2021 ident: 10.1016/S0140-6736(22)01656-7_bib25 article-title: Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study publication-title: Lancet doi: 10.1016/S0140-6736(21)00677-2 – volume: 22 start-page: 959 year: 2022 ident: 10.1016/S0140-6736(22)01656-7_bib4 article-title: Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(22)00141-4 – volume: 399 start-page: 36 year: 2022 ident: 10.1016/S0140-6736(22)01656-7_bib29 article-title: Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial publication-title: Lancet doi: 10.1016/S0140-6736(21)02718-5 – volume: 9 start-page: 1439 year: 2021 ident: 10.1016/S0140-6736(22)01656-7_bib23 article-title: COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(21)00380-5 – volume: 374 year: 2021 ident: 10.1016/S0140-6736(22)01656-7_bib3 article-title: COVID-19: booster doses to be offered to 30 million people in UK publication-title: BMJ – volume: 385 start-page: e84 year: 2021 ident: 10.1016/S0140-6736(22)01656-7_bib33 article-title: Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months publication-title: N Engl J Med doi: 10.1056/NEJMoa2114583 – volume: 1 start-page: 97 year: 2010 ident: 10.1016/S0140-6736(22)01656-7_bib24 article-title: A basic introduction to fixed-effect and random-effects models for meta-analysis publication-title: Res Synth Methods doi: 10.1002/jrsm.12 – volume: 327 start-page: 678 year: 2022 ident: 10.1016/S0140-6736(22)01656-7_bib32 article-title: Comparison of mRNA-1273 and BNT162b2 vaccines on breakthrough SARS-CoV-2 infections, hospitalizations, and death during the delta-predominant period publication-title: JAMA doi: 10.1001/jama.2022.0210 – volume: 9 start-page: 1439 year: 2021 ident: 10.1016/S0140-6736(22)01656-7_bib10 article-title: COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(21)00380-5 – volume: 9 start-page: 157 year: 2009 ident: 10.1016/S0140-6736(22)01656-7_bib20 article-title: The SAIL Databank: building a national architecture for e-health research and evaluation publication-title: BMC Health Serv Res doi: 10.1186/1472-6963-9-157 – year: 2021 ident: 10.1016/S0140-6736(22)01656-7_bib35 article-title: Examining the immunological effects of COVID-19 vaccination in patients with conditions potentially leading to diminished immune response capacity–the OCTAVE trial publication-title: SSRN doi: 10.2139/ssrn.3910058 – volume: 371 year: 2020 ident: 10.1016/S0140-6736(22)01656-7_bib16 article-title: Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study publication-title: BMJ – ident: 10.1016/S0140-6736(22)01656-7_bib17 doi: 10.2196/preprints.39141 – volume: 370 start-page: 1453 year: 2007 ident: 10.1016/S0140-6736(22)01656-7_bib15 article-title: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies publication-title: Lancet doi: 10.1016/S0140-6736(07)61602-X – volume: 385 start-page: 1393 year: 2021 ident: 10.1016/S0140-6736(22)01656-7_bib7 article-title: Protection of BNT162b2 vaccine booster against Covid-19 in Israel publication-title: N Engl J Med doi: 10.1056/NEJMoa2114255 – volume: 397 start-page: 1057 year: 2021 ident: 10.1016/S0140-6736(22)01656-7_bib31 article-title: Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals publication-title: Lancet doi: 10.1016/S0140-6736(21)00501-8 – volume: 398 start-page: 2093 year: 2021 ident: 10.1016/S0140-6736(22)01656-7_bib8 article-title: Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study publication-title: Lancet doi: 10.1016/S0140-6736(21)02249-2 – volume: 50 start-page: 1064 year: 2021 ident: 10.1016/S0140-6736(22)01656-7_bib18 article-title: Cohort profile: Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) Database publication-title: Int J Epidemiol doi: 10.1093/ije/dyab028 – volume: 386 start-page: 1207 year: 2022 ident: 10.1016/S0140-6736(22)01656-7_bib30 article-title: Protection against SARS-CoV-2 after COVID-19 vaccination and previous infection publication-title: N Engl J Med doi: 10.1056/NEJMoa2118691 – reference: 38521559 - Lancet. 2024 Mar 23;403(10432):1140. doi: 10.1016/S0140-6736(24)00493-8. – reference: 36244366 - Lancet. 2022 Oct 15;400(10360):1282-1283. doi: 10.1016/S0140-6736(22)01971-7. – reference: 37120280 - Lancet. 2023 Apr 29;401(10386):1423-1424. doi: 10.1016/S0140-6736(23)00443-9.
SSID	ssj0004605
Score	2.694517
Snippet	Current UK vaccination policy is to offer future COVID-19 booster doses to individuals at high risk of serious illness from COVID-19, but it is still uncertain... Summary Background Current UK vaccination policy is to offer future COVID-19 booster doses to individuals at high risk of serious illness from COVID-19, but it...
SourceID	pubmedcentral proquest pubmed crossref elsevier
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	1305
SubjectTerms	Aged BNT162 Vaccine ChAdOx1 nCoV-19 Cohort analysis Comorbidity Coronaviruses COVID-19 COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 Vaccines Datasets Death England - epidemiology Ethics Female Health care Hospitalization Humans Immunization Immunization, Secondary Immunosuppressive Agents Infections Kidney diseases Male Males Medical innovations Medical research Mortality mRNA Nations Northern Ireland Older people Pandemics Population Primary care Prospective Studies Regression analysis Regression models Risk analysis Risk factors Risk management SARS-CoV-2 Schedules Scotland Severe acute respiratory syndrome coronavirus 2 Vaccination Vaccines Viral diseases Wales - epidemiology
Title	Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S0140673622016567 https://dx.doi.org/10.1016/S0140-6736(22)01656-7 https://www.ncbi.nlm.nih.gov/pubmed/36244382 https://www.proquest.com/docview/2724592926 https://www.proquest.com/docview/2725445408 https://pubmed.ncbi.nlm.nih.gov/PMC9560746
Volume	400
WOSCitedRecordID	wos000898605000022&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M7P dateStart: 19920104 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0R dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7X7 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0T dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7RV dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: BENPR dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Research Library customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2O dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2M dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 8C1 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2P dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR1db9Mw0GIbQrwwvimMykg8gESY4zixs5dplE3soV21jtG3KHEcUWlKRpPu1_JjuHOcjMFgSDz0lMa-Okkv9-H7IuR1Eak893XsqVAaMFBk7KFW7flaapb7ElvL2mYTcjJR83k8dRtutQur7HiiZdR5pXGPfJtLLkKQ5TzaPf_mYdco9K66FhprZAOrJAQ2dG96XV6kDXG_zODZnvUn33D-FnN6Ik_-STb9rnv-GkL5k0w62Pzfu7lP7jltlO615POA3DLlQ3Jn7Pztj8j3mQFSN3R0dHr40fNjWq0aWMDU1PYWp7h5Ty9SDbPtP0yrgp639SsomM0gxs4MTcucLjBGCVYCnR4rM9Q7FHt7mRwG26IoiNltTMJPVF0GKMUOvsuG1m28I04LGMVeSbjcok8nq-GYuo4k76j1RpllSQ8xVwfPzHTVtEd4OV9ALNaPyeeD_ZPRJ8_1g_A06F0NUFIkuTGZyPOMaZExo1imtSh4VAQyhU-WG14YMKlYFqYqjTKhlcgZ2JgiVFHwhKyXVWmeERoUOkxDHmuVBiJWTAkwg00qpADszFcDIjpKSLQrlo49O86Sa6LiOE8sASVyQN73aO5p34QQdWSWdKmwwLwTkGc3Iaoe0elKrQ70L6hbHU0mjmHVySVBDsirfhhYDfqP0tJUKzsHSzcJBo_naUv-_V2CHiTQpzwg8sqL0U_AMuZXR8rFV1vOHC10KaLnf7-sF-Qux8wTDCYKt8h6s1yZl-S2vmgW9XJI1uTxKcK5tFABVCN_SDY-7E-mx_BtzFp4gpCPLTyycDq0XOMHl1VoUQ
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKQcCF92OhgJFAAolQx3FiBwkh1FJ11e6CtFvoLSS2I1aqkrLJFvGn-EX8GGacRykUyqUHDitFsSdxvDOeGXtmPkIe5ZEyxtexp0JpwUGRsYdWtedrqZnxJULLOrAJOR6r3d343RL51uXCYFhltya6hdqUGvfIV7nkIgRdzqNX-589RI3C09UOQqNhiy379Qu4bNXL4Tr8v48533gzXdv0WlQBT4P2rmE8keTWZsKYjGmRMatYprXIeZQHMoVfZizPLRjmLAtTlUaZ0EoYBp6KCFUUwHPPkLNYVw9DCEdselwepgupP8wYWp30N59w_hRziCJP_kkX_m7r_hqy-ZMO3Lj8v83eFXKptbbp60Y8rpIlW1wj50dtPMF18n1iQZQtXXv7frju-TEtFzV8kK2ow06neDhBD1INvR0H0zKn-019DloBu5vFnqVpYegMY7DgTeCzYOWJ6gVF7DJroLEp-oKU3cYrPKLsMlwpIhTPa1o18ZzYLWAUsaDwdbM-Xa6Ca9oirjyj7rTNzgs6xFwkvDPRZd1c4XA-gNqvbpCdU5nbm2S5KAt7m9Ag12Ea8lirNBCxYkqAm29TIQVQZ74aENFxXqLbYvCISbKXHBP1x3niGDaRA_K8J2tn-ySCqGPrpEv1BeWUgL4-iVD1hK0t2Nh4_0K60slA0i7IVXIoAAPysG-GpRTPx9LClgvXB0tTCQbTc6sRt_4rwc4TeGY-IPKIIPYdsEz70ZZi9smVa8cdCCmiO38f1gNyYXM62k62h-Otu-QixywbDJwKV8hyPV_Ye-ScPqhn1fy-W3Mo-XjaYvoDjA68jg
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgiouvB8LBYwEEkiETRwndpAQQrusWBWWSsujt5DYjlipSsomW8Rf47fwY5jJqxQK5dIDh0hR7ElsZ8YztmfmA7iXhcoYT0eOCqTFBYqMHLKqHU9L7RpPErRsDTYhZzO1sxNtr8G3LhaG3Cq7ObGeqE2haY98yCUXAepyHg6z1i1iezx5tvfZIQQpOmnt4DQaFtmyX7_g8q18Oh3jv77P-eTF29FLp0UYcDRq8grbFkpubSqMSV0tUtcqN9VaZDzMfJnglRrLM4tGupsGiUrCVGgljIurFhGo0Mf3noLT0kcupij1kXdUTGbtXn8QPTSc9w8fcP6Q4olCR_5JL_5u9_7qvvmTPpyc_59H8gKca61w9rwRm4uwZvNLsPG69TO4DN_nFkXcstGb99Ox40WsWFXYOVuyGlOdUY_YfqKxds3ZrMjYXpO3g5UoBma1a1mSG7Yg3yz8Eq5lKCNF-YQRppk1WNgkgyHKbkMWX1F0ka-MkIuXFSsbP0-q5ruMMKLoc4s-jK7Ee9YisTxi9SmcXeZsSjFK9GSui6q5o-Z8QHOgvALvTmRsr8J6XuT2OjA_00ES8EirxBeRcpXA5b9NhBRInXpqAKLjwli3SeIJq2Q3PsIbkPO4Zt5YDuBxT9aO9nEEYcficRcCjEorRj1-HKHqCVsbsbH9_oV0s5OHuJ2oy_hAGAZwty_GKZbOzZLcFqu6DqWsEi4Oz7VG9Ppeov0n6Cx9APKQUPYVKH374ZJ88alO4047E1KEN_7erDuwgdIZv5rOtm7CWU7BN-RPFWzCerVc2VtwRu9Xi3J5u55-GHw8aSn9AcvwxQw
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Severe+COVID-19+outcomes+after+full+vaccination+of+primary+schedule+and+initial+boosters%3A+pooled+analysis+of+national+prospective+cohort+studies+of+30+million+individuals+in+England%2C+Northern+Ireland%2C+Scotland%2C+and+Wales&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Agrawal%2C+Utkarsh&rft.au=Bedston%2C+Stuart&rft.au=McCowan%2C+Colin&rft.au=Oke%2C+Jason&rft.date=2022-10-15&rft.pub=Elsevier+Ltd&rft.issn=0140-6736&rft.volume=400&rft.issue=10360&rft.spage=1305&rft.epage=1320&rft_id=info:doi/10.1016%2FS0140-6736%2822%2901656-7&rft.externalDocID=S0140673622016567
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0140-6736&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0140-6736&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0140-6736&client=summon